Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBITDA Margin (2020 - 2025)

GeneDx Holdings (WGS) has disclosed EBITDA Margin for 6 consecutive years, with 14.66% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 2025.0% to 14.66% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.89%, a 1209.0% increase, with the full-year FY2025 number at 4.89%, up 1209.0% from a year prior.
  • EBITDA Margin was 14.66% for Q4 2025 at GeneDx Holdings, down from 6.38% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 6393.49% in Q2 2021 to a low of 503.28% in Q4 2022.
  • A 5-year average of 233.39% and a median of 42.64% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -663055bps in 2022, then skyrocketed 45913bps in 2023.
  • GeneDx Holdings' EBITDA Margin stood at 69.52% in 2021, then plummeted by -624bps to 503.28% in 2022, then soared by 91bps to 44.15% in 2023, then soared by 113bps to 5.59% in 2024, then crashed by -362bps to 14.66% in 2025.
  • Per Business Quant, the three most recent readings for WGS's EBITDA Margin are 14.66% (Q4 2025), 6.38% (Q3 2025), and 10.44% (Q2 2025).